Temozolomide and Hypothyroidism - a phase IV clinical study of FDA data

Summary:

Hypothyroidism is reported as a side effect among people who take Temozolomide (temozolomide), especially for people who are male, 10-19 old, have been taking the drug for < 1 month also take Carboplatin, and have Medulloblastoma.

The phase IV clinical study analyzes which people have Hypothyroidism when taking Temozolomide. It is created by eHealthMe based on reports of 16,598 people who have side effects when taking Temozolomide from the FDA, and is updated regularly.

What is Temozolomide?

Temozolomide has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 16,644 Temozolomide users. Check the latest studies of Temozolomide.

What is Hypothyroidism?

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development) is found to be associated with 1,614 drugs and 2,598 conditions by eHealthMe. Check the latest studies of Hypothyroidism.

On Jul, 08, 2026

16,598 people reported to have side effects when taking Temozolomide.
Among them, 29 people (0.17%) have Hypothyroidism.

Could Temozolomide cause Hypothyroidism?

Among these 29 people:

How long have people been on Temozolomide when they have Hypothyroidism? *

What is the gender of people who have Hypothyroidism when taking Temozolomide? *

female: 39.13 %
male: 60.87 %

What is the age of people who have Hypothyroidism when taking Temozolomide? *

What are other drugs people take besides Temozolomide? *

What are other side effects people have besides Hypothyroidism? *

Coordination Abnormal (abnormal movement): 11 people, 37.93%
Visual Impairment: 11 people, 37.93%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 11 people, 37.93%
Speech Impairment (Adult) (inability to speak (adult)): 11 people, 37.93%
Movement - Uncoordinated: 11 people, 37.93%
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 10 people, 34.48%
Nausea (feeling of having an urge to vomit): 6 people, 20.69%
Diarrhea: 5 people, 17.24%
Nausea And Vomiting: 5 people, 17.24%
Fatigue (feeling of tiredness): 5 people, 17.24%

What are the existing conditions these people have? *

Medulloblastoma (a fast-growing, high-grade tumour that always begins in the cerebellum): 11 people, 37.93%
Neuroblastoma (a cancer that forms in your nerve tissue): 4 people, 13.79%
Urinary Tract Infection: 2 people, 6.90%
Radiation Injury (injuries are caused by radiation): 2 people, 6.90%
Neoplasm Malignant (cancer tumour): 2 people, 6.90%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 6.90%
Diabetes: 2 people, 6.90%
Anaplastic Astrocytoma (tumour of the glial (supportive) tissue of the brain): 2 people, 6.90%
Ovarian Cancer (cancer of ovary): 1 person, 3.45%
Osteoporosis (bones weak and more likely to break): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Temozolomide and have Hypothyroidism?

- Check whether Hypothyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temozolomide:

Temozolomide (16,644 reports)

Hypothyroidism treatments and more:

Hypothyroidism (168,065 reports)

Browse all side effects of Temozolomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypothyroidism:

Hypothyroidism (1,614 drugs)

Browse all the conditions that are associated with Hypothyroidism:

Hypothyroidism (2,598 conditions)

Related publications that referenced our studies

Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .
Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .

How the study uses the data?

The study uses data from the FDA. It is based on temozolomide (the active ingredients of Temozolomide) and Temozolomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.